Sanofi - Aventis Groupe: Press release: New Phase 3 data pre

New Phase 3 data presented at WORLDSymposium reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease Paris

Related Keywords

Australia , Taiwan , Japan , United States , Paris , France General , France , United Kingdom , Argentina , Brazil , United Arab Emirates , Canada , South Korea , Switzerland , Dennis Riedl , Eva Schaefer Jansen , Worldsymposiumreinforce Nexviazyme , Corentine Driancourt , Felix Lauscher , Priyas Kishnani , Kate Conway , Tarik Elgoutni , Nathalie Pham , Sandrine Guendoul , Duke University Medical Center , European Union , Genomics Center , Nasdaq , Euronext , New Phase , Medical Director , Alice Chen Pediatrics Genetics , Division Chief , Medical Genetics , Specialty Care , About Pompe , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Sanofi , Eventis , Roupe , Dress , Release , Hase , Data , Resented , Orldsymposium , Reinforce , Exviazyme , Valglucosidase , Alfa , Potential , Standard , Mare , People , Diving , Gate , Onset , Pompe , Disease ,